Raloxifene improves TNF‑α‑induced osteogenic differentiation inhibition of bone marrow mesenchymal stem cells and alleviates osteoporosis

Yang,Fenghe; Jia,Yusong; Sun,Qi; Zheng,Chenying; Liu,Chuyin; Wang,Wei; Du,Li; Kang,Shengqian; Niu,Xufeng; Li,Jinyu

doi:10.3892/etm.2020.8689

Raloxifene improves TNF‑α‑induced osteogenic differentiation inhibition of bone marrow mesenchymal stem cells and alleviates osteoporosis

Authors:
- Fenghe Yang
- Yusong Jia
- Qi Sun
- Chenying Zheng
- Chuyin Liu
- Wei Wang
- Li Du
- Shengqian Kang
- Xufeng Niu
- Jinyu Li
View Affiliations

Affiliations: Key Laboratory for Biomechanics and Mechanobiology of Ministry of Education, School of Biological Science and Medical Engineering, Beihang University, Beijing 100083, P.R. China, Department of Orthopaedics, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, P.R. China
Published online on: April 27, 2020 https://doi.org/10.3892/etm.2020.8689
Pages: 309-314
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effect of raloxifene (RLF) on the improvement of inhibited osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) resulted from tumor necrosis factor‑α (TNF‑α) induction, thus alleviating the progression of osteoporosis (OP), was investigated. An in vivo OP rat model was constructed by performing the procedures of ovariectomy (OVX). Rats were randomly divided into sham group, OVX group and RLF+OVX group. BMSCs were extracted from healthy rats, and randomly divided into control group, TNF‑α group, RLF group and TNF‑α+RLF group. Viability and cellular calcification ability in each group were detected. The relative levels of osteocalcin (OCN), Runx2 and NF‑κB in cells with different treatments were determined. The body weight of rats in the OVX group and RLF+OVX group gradually increased compared with that in the sham group on the 8th week. No significant difference in body weight was observed between the rats of the OVX group and RLF+OVX group. Bone metabolism index (BMD) in the rats of the RLF+OVX group was higher than that of the OVX group, and lower compared with that of the sham group. Compared with the sham group, the elastic/max radial degree and elastic/max load of femora were reduced in the OVX group and RLF+OVX group, especially in the OVX group. The relative levels of OCN and Runx2, as well as the ALP activity and calcification ability, were decreased in the OVX group compared with the sham group, and the effect was partially reversed by the RLF treatment. After osteogenic differentiation of BMSCs, the viability and calcification ability were markedly reduced in TNF‑α group, which was reversed by RLF treatment. Moreover, TNF‑α induction downregulated the relative levels of OCN and Runx2, and RLF treatment could enhance their levels. The upregulated NF‑κB protein level, induced by TNF‑α, was reduced after RLF treatment. TNF‑α induction inhibits osteogenic differentiation of BMSCs, which could be remarkably alleviated by RLF. It is suggested that RLF contributes to the alleviation of OP progression.

View Figures

View References

1	Hu BT and Chen WZ: MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-β/Smad pathway. Eur Rev Med Pharmacol Sci. 22:7156–7163. 2018.PubMed/NCBI View Article : Google Scholar
2	Zhu H, Fang J, Luo X, Yu W, Zhao Y, Li X, Du J and Lu Y: A survey of bone mineral density of healthy Han adults in China. Osteoporos Int. 21:765–772. 2010.PubMed/NCBI View Article : Google Scholar
3	Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B and Kanis JA: Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 8(136)2013.PubMed/NCBI View Article : Google Scholar
4	Chavassieux P, Portero-Muzy N, Roux JP, Garnero P and Chapurlat R: Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women? J Clin Endocrinol Metab. 100:4662–4668. 2015.PubMed/NCBI View Article : Google Scholar
5	Rodan GA and Martin TJ: Therapeutic approaches to bone diseases. Science. 289:1508–1514. 2000.PubMed/NCBI View Article : Google Scholar
6	Brennan TC, Rizzoli R and Ammann P: Selective modification of bone quality by PTH, pamidronate, or raloxifene. J Bone Miner Res. 24:800–808. 2009.PubMed/NCBI View Article : Google Scholar
7	Lamas AZ, Caliman IF, Dalpiaz PL, de Melo AF Jr, Abreu GR, Lemos EM, Gouvea SA and Bissoli NS: Comparative effects of estrogen, raloxifene and tamoxifen on endothelial dysfunction, inflammatory markers and oxidative stress in ovariectomized rats. Life Sci. 124:101–109. 2015.PubMed/NCBI View Article : Google Scholar
8	Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, et al: Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA. 282:637–645. 1999.PubMed/NCBI View Article : Google Scholar
9	Ding J, Ghali O, Lencel P, Broux O, Chauveau C, Devedjian JC, Hardouin P and Magne D: TNF-alpha and IL-1beta inhibit RUNX2 and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. Life Sci. 84:499–504. 2009.PubMed/NCBI View Article : Google Scholar
10	Qiu W, Andersen TE, Bollerslev J, Mandrup S, Abdallah BM and Kassem M: Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells. J Bone Miner Res. 22:1720–1731. 2007.PubMed/NCBI View Article : Google Scholar
11	Mukai T, Otsuka F, Otani H, Yamashita M, Takasugi K, Inagaki K, Yamamura M and Makino H: TNF-alpha inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. Biochem Biophys Res Commun. 356:1004–1010. 2007.PubMed/NCBI View Article : Google Scholar
12	Chang J, Liu F, Lee M, Wu B, Ting K, Zara JN, Soo C, Al Hezaimi K, Zou W, Chen X, et al: NF-κB inhibits osteogenic differentiation of mesenchymal stem cells by promoting β-catenin degradation. Proc Natl Acad Sci USA. 110:9469–9474. 2013.PubMed/NCBI View Article : Google Scholar
13	Gilbert L, He X, Farmer P, Rubin J, Drissi H, van Wijnen AJ, Lian JB, Stein GS and Nanes MS: Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem. 277:2695–2701. 2002.PubMed/NCBI View Article : Google Scholar
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
15	Kemmler W, Häberle L and von Stengel S: Effects of exercise on fracture reduction in older adults: A systematic review and meta-analysis. Osteoporos Int. 24:1937–1950. 2013.PubMed/NCBI View Article : Google Scholar
16	Harvey N, Dennison E and Cooper C: Osteoporosis: Impact on health and economics. Nat Rev Rheumatol. 6:99–105. 2010.PubMed/NCBI View Article : Google Scholar
17	Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al: Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA. 288:321–333. 2002.PubMed/NCBI View Article : Google Scholar
18	Passeri G, Girasole G, Jilka RL and Manolagas SC: Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology. 133:822–828. 1993.PubMed/NCBI View Article : Google Scholar
19	Vitale RF and Ribeiro FA: The role of tumor necrosis factor-alpha (TNF-alpha) in bone resorption present in middle ear cholesteatoma. Rev Bras Otorrinolaringol (Engl Ed). 73:117–121. 2007.PubMed/NCBI View Article : Google Scholar
20	Rayl JM, Wellehan JFX Jr, Bunick D and Allender MC: Development of reverse-transcriptase quantitative PCR assays for detection of the cytokines IL-1β, TNF-α, and IL-10 in chelonians. Cytokine. 119:16–23. 2019.PubMed/NCBI View Article : Google Scholar
21	Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G and Pacifici R: Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA. 98:13960–13965. 2001.PubMed/NCBI View Article : Google Scholar
22	An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N and Leitman DC: Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem. 276:17808–17814. 2001.PubMed/NCBI View Article : Google Scholar